Evidence map›Paper›PMID 40475167›Full record

ArticleMolecular syndromology2025

Evaluation of Cardiomyopathy-Related Target Genes by Next-Generation Sequencing Method and Investigation of the Phenotype-Genotype Relationship.

Hazal Sezginer Guler, Drenushe Zhuri, Sinem Yalcintepe, Servet Altay, Murat Deveci, Selma Demir, Hanefi Yekta Gurlertop, Engin Atli, Emine İkbal Atli, Hakan Gurkan

Abstract read
In one paragraph

Article in Molecular syndromology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hazal Sezginer GulerDepartmant of Medical Genetics, Faculty of Medicine, Trakya University, Edirne, Turkey.
Drenushe ZhuriDepartmant of Medical Genetics, Faculty of Medicine, Trakya University, Edirne, Turkey.
Sinem YalcintepeDepartmant of Medical Genetics, Faculty of Medicine, Trakya University, Edirne, Turkey.
Servet AltayDepartmant of Cardiology, Faculty of Medicine, Trakya University, Edirne, Turkey.
Murat DeveciDepartmant of Pediatric Cardiology, Faculty of Medicine, Trakya University, Edirne, Turkey.
Selma DemirDepartmant of Medical Genetics, Faculty of Medicine, Trakya University, Edirne, Turkey.
Hanefi Yekta GurlertopDepartmant of Cardiology, Faculty of Medicine, Trakya University, Edirne, Turkey.
Engin AtliDepartmant of Medical Genetics, Faculty of Medicine, Trakya University, Edirne, Turkey.
Emine İkbal AtliDepartmant of Medical Genetics, Faculty of Medicine, Trakya University, Edirne, Turkey.
Hakan GurkanDepartmant of Medical Genetics, Faculty of Medicine, Trakya University, Edirne, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Primary heart muscle diseases called cardiomyopathy (CMP) constitute an important group of subsequent heart disorders. CMPs are basically divided into four subgroups associated with the heart muscle but clinically distinguishable: hypertrophic CMP (HCM), dilated CMP (DCM), restrictive CMP (RCM), and left ventricular non-compaction CMP. Material and Methods: The results of the patients who applied to the Genetic Diseases Evaluation Center with the preliminary diagnosis of clinical CMP were evaluated retrospectively in the current study. In the current study, 103 cases were included and evaluated for phenotype-genotype association with the CMP next-generation sequencing (NGS) panel. Results: Fifty-eight different variants were identified in 45 patients. Sixteen out of those 58 variants were novel. Of these variants, 19 (32.75%) were likely pathogenic (LP)/pathogenic (P), and 35 (60.34%) were variants of uncertain significance. Conclusion: The prevalence of pathogenic variants in target genes associated with CMP is important for our current country's population, and multiple gene groups associated with CMP can be screened through NGS. The contribution rate to the clinical diagnosis was 18.44% in terms of the individual population who applied to our medical genetics center and were compatible with the CMP indication.

Indexed as

CardiomyopathyGenotypeNext-generation sequencingPhenotypeTargeted genes

Identifiers

PMID40475167
PMCPMC12136558

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.